Dr Rajendran C Gopalan
|Position||Lecturer in Pharmacology|
|Location||M30b Richmond Building|
|Department||School of Pharmacy and Medical Sciences|
|Telephone||+44 (0) 1274 234771|
Research Interests (key words only)
In Vitro nano toxicology, Inflammtory responses, peristalsis.
Co supervisor for 2 PhD and 1 DPharm student
Projects supervised - Biomarkers of Genotoxic and reprotoxic effects after chemical exposure
Teaching and Supervisory Responsibilities
Master of Pharmacy (MPharm):
- Module leader: Transport 1 (Stage 2, MPharm)
- Unit leader: Transport Systems 1 Unit 2 and 3 Cardiovascular system 1
- Module Leader: Synoptic assessments (Stage 2, MPharm)
- Stage 4 SSC Projects
- Delivering lab sessions: Nutrition Metabolism and Reproduction 1 and 2
Clinical Sciences (B.Sc.):
- Endocrinology and Neurobiology ( PH 5114L) Stage 2: lectures and tutorials
- Common Diseases and their Treatment (PH8312D) Stage 3
- CNS Mechanisms, Disorders and Therapeutics (CS-6004D) Stage 3
- Module leader: Transport systems 1, Transport systems 2 and Synoptic assessments stage 2
- Nominated Theme Lead: Pharmacology/Human Biology/Biology of Disease: Medical School Curriculum development (June 2017 to date)
- Member of Steering Group: GPhC accreditation of MPharm Curriculum 2018 (May 2016 to date)
- Member of Task and Finish Group 1 for GPhC accreditation of MPharm Curriculum 2018 (May 2016 to date)
- Member of the University of Bradford International Foundation Year Biology Module Creation Committee (April 2017 to date)
- Represents the University at the National group for embedding the Top 100 Drugs in the MPharm curriculum across England and Wales and also the development of an app for the same. (Dec 2015 to date)
- Academic lead for implementation of the Top 100 Drugs in Bradford School of Pharmacy and Medical Sciences MPharm curriculum Since Dec 2015)
- Panel member: Approval committee for the new programmes at the University of Bradford
- 2011- to present: Lecturer in Pharmacology
- 2009 - January 2011: Lecturer in Pharmacology (Part time)
- 2008 - June 2009: Lecturer (part time), University of Bradford
- 2007 to 2008: Lecturer in Physiology and Pharmacology, University of Bradford
- 2006 to 2007: Post doctoral Researcher, Project Funded by Yorkshire forward
- 2004 to 2005: Visiting Researcher, University of Bradford
- B.Sc. University of Mumbai, India
- M.Sc. (Specialisation :Physiology) University of Mumbai, India
- Ph.D. University of Mumbai, India
- PGCHEP University of Bradford, UK
- Senior Fellow of Higher Education Academy
- Member United Kingdom Mutagen Society
Currently I am investigating * the potential and genotoxicity of naturally occurring compounds * genotoxixcity of thermal extrusion products and I am co-supervising two PhD student researching in the area of toxicology of nanomaterials.
PhD projects: Biomarkers of Genotoxic and reprotoxic effects after exposure in human
Genotoxicology Research collaborators:
- Prof Diana Anderson University of Bradford
- Prof Anant Paradkar University of Bradford
- Dr Maojgan Najafzadeh University of Bradford
- Dr Khaled Assi University of Bradford
Educational Research collaborators:
- Prof Tim Palmer University of Bradford
- Dr Diana Wood University of Bradford
- Dr Bishwa Tuladhar University of Bradford
- Darren Brown University of Bradford
Najafzadeh M, Normington C, Jacob BK, Isreb M, Gopalan RC, Anderson D. (2016) DNA damage in healthy individuals and respiratory patients after treating whole blood in vitro with the bulk and nano forms of NSAIDs. Front Mol Biosci. 3:50. eCollection 2016.
Effect of Drinking Water Disinfection By-Products in Human Peripheral Blood Lymphocytes and Sperm. Aftab Ali, Malgorzata Kurzawa-Zegota, Mojgan Najafzadeh, Rajendran C Gopalan, Michael J Plewa, Diana Anderson. Mutation Research:Fundamental and Molecular Mechanisms of Mutagenesis. 08/2014 (Impact factor 4.440)DOI: 10.1016/j.mrfmmm.2014.08.003)
Sensitivity and Specificity of the Empirical Lymphocyte Genome Sensitivity (LGS) Assay: Implications for Improving Cancer Diagnostics: Diana Anderson, Mojgan Najafzadeh, Rajendran Gopalan, Nader Ghaderi, Andrew J Scally, Stephen T Britland, Badie K Jacobs, P Dominic Reynolds, Justin Davies, Andrew L Wright, Shariff Al-Ghazal, David Sharpe, Morgan C Denyer . FASEB Journal 07/2014 (Impact factor 5.480) FASEB J fj.14-254748; published ahead of print July 25, 2014, doi:10.1096/fj.14-254748
In vitro sensitivities to UVA of lymphocytes from patients with colon and melanoma cancers and precancerous states in the micronucleus and the Comet assays
Mutagenesis 12/2011; DOI: 10.1093/mutage/ger087
Effects of the anti-malarial compound cryptolepine and its analogues in human lymphocytes and sperm in the Comet assay
Toxicology letters 09/2011; DOI: 10.1016/j.toxlet.2011.09.010
"The effect of zinc oxide and titanium dioxide nanoparticles in the Comet assay with UVA photoactivation of human sperm and lymphocytes"
Rajendran C. Gopalan; Ilham F. Osman; Amir Amani; Marcel De Matas; Diana Anderson Nanotoxicology, Volume 3, Issue 1, 2009 , pages 33 - 39 .
Techniques for cryopreservation of intestinal smooth muscle cells.
Samira Lobo, Morgan Denyer, Rajendran C Gopalan and Farida javid. Cryobiology 57(2008): 186 -189.
Patent: UV sensitivity Assay, UK patent No. 0621272.4, 2007.
Morgan Denyer, Stephen Britland, David Sharpe, Diana Anderson, Rajendran C Gopalan and University of Bradford.
Effects of Sex Hormones and their modulators on DNA damage in skin cells measured in the Comet assay.
Rajendran C Gopalan, Louisa D Nelson, Julie M Thornton, Diana Anderson (2006). The Journal of Preventive Medicine; 14(1-2): 14-31.
The 3D UVA sensitivity assay co-invented by me and my colleagues at the University of Bradford is the basis of the development of a spinoff company, Oncascan, through the Knowledge Transfer(KT) support of the University of which I am a shareholder along with other colleagues and the University of Bradford. This Oxfordshire based company has branded and licensed the “3D UVA assay” as the “Lymphocyte Genome Sensitivity Test (LGS Test)” as a reliable and practical rule out test for cancer. The LGS Test is aimed at patients who have reported potential cancer symptoms to their GP and are being referred to their local hospital for further investigation.
Whilst it is very important to identify cancer as early as possible, many of the current investigations that lead to diagnosis are invasive and, the vast majority of the time, they are negative. This sets up a tension which the LGS Test aims to relieve by safely identifying, at an early stage, a large proportion of those who do not have cancer. This potentially has high impact in terms of patient benefit and costs to the NHS. This evidences my contribution to the development of knowledge and practices in my own field, and also resolving complex research related problems using creativity while ensuring compliance with appropriate regulations and policies.
I represented the University of Bradford at the National group formed to agree upon and develop a computer application for the common top hundred drugs to inform the students registered on the MPharm programme across UK. I was part of the University team that was one of the only three finalists in the Medical Devices and Diagnostics category, for the simple blood test developed to detect individuals with cancer at the eleventh annual Medipex Innovation Awards and Showcase October 8, 2015, organised by Medipex Ltd, the innovation hub for NHS organisations in Yorkshire and the Humber and the East Midlands.
Table lead (Topics for MPharm Curriculum): Stake holders meeting Patients, industry and government organisation as part of the steering committee which is responsible for the updating of MPharm curriculum and preparing the documentation for the next GPhC accreditation in 2018.